New Laser and Suction Sheath for Kidney Stone Treatment
NCT ID: NCT06667466
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
140 participants
OBSERVATIONAL
2026-11-20
2027-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does the sTFL with a flexible negative pressure suction sheath have a higher stone - free rate than the sTFL with a conventional sheath? Does the sTFL with a flexible negative pressure suction sheath have fewer complications than the sTFL with a conventional sheath?
Researchers will compare the two treatment groups to see if there are differences in stone - free rate and complication rates.
Participants will:
Undergo ureteroscopic lithotripsy surgery. In the experimental group, have a flexible negative pressure suction sheath inserted along a guidewire to the stone site under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz while the fragments are removed by negative pressure suction.
In the control group, have a conventional sheath inserted to the upper ureter or the ureteropelvic junction under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz and the fragments removed by a stone basket.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Super Pulse Fiber Thulium Laser and Holmium Laser for Ureteral Stone Fragmentation During Ureteroscopy
NCT06667557
Super-Pulsed Thulium Fiber Laser Versus Holmium:YAG Laser in Retrograde Intrarenal Surgery for Upper Ureteral and Renal Stones
NCT07012941
Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
NCT06721975
Ureteroscopy Combined With Negative Pressure Sheath Treatment of Kidney Stones
NCT06938113
Efficacy of Semi-rigid Ureteroscopic Laser Lithotripsy in the Treatment of Proximal Ureteral Stones: a Randomized Controlled Trial
NCT06489366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Background and Rationale Urinary calculi are common, with a significant recurrence rate. Incomplete stone removal during treatment is a contributing factor to recurrence. The flexible negative pressure suction sheath offers potential advantages over the conventional sheath, and when combined with the high-performance sTFL, may provide better treatment outcomes. However, a clinical comparison of these combinations has been lacking.
2. Study Design
Multicenter: Involving hospitals such as Shanghai Jiao Tong University School of Medicine Affiliated First People's Hospital, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, and Weifang Hospital of Traditional Chinese Medicine.
Randomization: Simple randomization is used, with a 1:1 ratio of participants assigned to the experimental group (sTFL + flexible negative pressure suction sheath) and the control group (sTFL + conventional sheath) via a central randomization system.
Blinding: A third-party independent assessment method is employed. Two radiologists blinded to the patient's group and clinical information will evaluate the CT scans at 3 months postoperatively to determine the stone - free rate.
3. Participants
Inclusion Criteria: Adults aged 18 years or older, diagnosed with kidney stones and/or ureteral stones with a diameter between 6mm and 20mm, scheduled for ureteroscopic lithotripsy (fURS) under general anesthesia, with a negative preoperative urine culture, and having provided informed consent.
Exclusion Criteria: Isolated kidney, history of kidney transplant or urinary diversion surgery, congenital urinary tract anomalies, coagulation disorders, severe cardiac or pulmonary diseases, malignant tumors, immunodeficiency, neurogenic bladder, inability to provide informed consent, untreated urinary tract infection, known anatomical abnormalities preventing sheath access to the stone or relevant sites, pregnancy, and those who cannot be treated under the specified anesthesia methods.
4. Interventions
Experimental Group: Under general anesthesia, a flexible negative pressure suction sheath is inserted along a guidewire to the stone site, followed by insertion of a ureteroscope through the sheath to the stone site. The sTFL is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz, while the fragments are removed by negative pressure suction.
Control Group: Under general anesthesia, a conventional sheath is inserted to the upper ureter or the ureteropelvic junction, followed by insertion of a ureteroscope through the sheath to the stone site. The sTFL is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz, and the fragments are removed by a stone basket.
5. Outcome Measures
Primary Outcome Measure: Stone - free rate (SFR), evaluated by non - contrast CT scan at 3 months postoperatively, defined as residual stone diameter \< 2mm.
Secondary Outcome Measures: Surgery time, complication rates (including intraoperative and postoperative complications such as infection, bleeding, and instrument - related injuries), and changes in vital signs (temperature, pulse, respiration, blood pressure).
6. Safety Assessment
Adverse Events (AE) and Serious Adverse Events (SAE): All AEs and SAEs are monitored, recorded, and reported. AE details include name, occurrence and resolution dates, severity, impact on the study, relationship to the study, measures taken, and outcome. SAEs must be reported to the ethics committee within 24 hours.
Vital Signs Monitoring: Vital signs are monitored before, during, and within 24 hours after surgery.
Complication Assessment: Postoperative complications are assessed using the Clavien - Dindo grading system.
7. Sample Size Calculation Based on an assumed superiority of the experimental treatment, with a clinically significant difference in SFR of 5% between the two groups, a sample size of 67 participants per group (considering a 20% dropout rate) was calculated, totaling 134 participants, and the study aims to recruit 140 participants.
8. Data Analysis Descriptive statistics (means and standard deviations for continuous variables, frequencies and percentages for categorical variables) and comparison tests (t - test for continuous variables, Fisher's exact test for categorical variables) will be used. All analyses will be performed using R software version 4.3, with a significance level of P \< 0.05.
9. Follow - up Plan
Baseline Visit (Screening Period): Assess potential participants for eligibility, including collecting demographic data, medical history, measuring vital signs, and performing a CT scan.
Intraoperative Visit (Treatment Period): Record surgery time, instrument usage, and monitor vital signs and complications.
Postoperative 24 - hour Visit (Treatment Period): Monitor vital signs, ask about symptoms, and check for complications.
Postoperative 90 - day Visit (Follow - up Period): Evaluate stone clearance by CT scan and assess symptom recovery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sTFL + Flexible Negative-Pressure UAS
Under general anesthesia, a guidewire is first inserted. Then, the Flexible Negative Pressure UAS is inserted along the guidewire to the stone site. A ureteroscope is inserted through the sheath to the stone site. The sTFL is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz. Simultaneously, the fragmented stones are removed by negative pressure suction.
Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention
The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
sTFL + Conventional UAS
Under general anesthesia, the Conventional UAS is inserted to the upper ureter or the ureteropelvic junction. A ureteroscope is inserted through the sheath to the stone site. The sTFT is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz. After fragmentation, the stones are removed by a stone basket.
Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention
The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention
The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention
The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with kidney stones and/or ureteral stones, and stone diameter is ≥6mm and ≤20mm
* Plan to undergo fURS lithotripsy
* General anesthesia to complete the operation
* The latest urine culture before surgery is negative
* Signed and dated informed consent
Exclusion Criteria
* Previous history of kidney transplantation or urinary diversion surgery
* Congenital malformations of urinary system
* Abnormal coagulation mechanism due to blood system diseases, liver diseases, etc
* Severe heart or lung disease, malignancy and immune deficiency status
* Neurogenic bladder
* Failure to provide informed consent
* Have an untreated urinary tract infection
* The presence of known anatomic abnormalities (such as ureteral stenosis), urothelial tumors, or stones that can be removed directly without the use of laser lithotripsy
* Pregnant women
* In cases where the stone cannot be reached with a bendable negative pressure suction sheath, or in cases where the stone cannot be reached with a conventional sheath or the pyeloureteral junction
* Epidural anesthesia or lumbar anesthesia to complete the operation
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yi Shao
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yi Shao
Role: PRINCIPAL_INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT2024-148
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.